The disclosure concerns cancer immunotherapy and configuring the immunotherapy with modular molecular adaptors. In certain embodiments, there is an immune effector cell, wherein the cell produces a molecular adaptor comprising: (a) a tumor cell binding domain, and (b) a cytokine domain comprising (i) a cytokine or a functional fragment thereof; or (ii) a cytokine receptor or a functional fragment thereof; or (iii) a combination of both (i) and (ii); (c) optionally further comprising an antigen receptor target domain; optionally wherein the cell comprises one or more engineered antigen receptors against one or more tumor target antigens.
展开▼
